This is an abstract of the Plain Language Summary of Publication article .
To read the full Plain Language Summary of this article, click here to view the PDF .
Link to original article here
Acknowledgments
The authors of this article thank the people who participated in this study and their families, as well as the investigators, co-investigators, and staff at each of the clinical sites. Patients treated at Memorial Sloan Kettering Cancer Center were supported in part by Memorial Sloan Kettering Cancer Center Support Grant (Core Grant, number P30 CA008748).
Funding
This manuscript was funded by Ipsen. The manuscript was also reviewed and approved by Ipsen and Bristol Myers Squibb.
Financial & competing interests disclosure
Research reported in this publication was funded in part by Janssen Oncology research and designed in partnership with Alliance Foundation Trials ( https://acknowledgments.alliancefound.org ). PMV served as a consultant for, received honoraria from, and holds a membership on an entity's board of directors or advisory committees for AbbVie, Amgen, Bristol Myers Squibb, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Sanofi, and Secura Bio. DWS served as a consultant for and holds membership on an entity's board of directors or advisory committees for Janssen, Arcellx, AbbVie, Pfizer, Sanofi, and Bioline; and served as a consultant for Pfizer, GSK, and Sanofi. JL received honoraria from Great Debates & Updates – Hematologic Malignancies. JLK served as a consultant for AbbVie, Bristol Myers Squibb, Heidelberg Pharma, Incyte, Janssen, Novartis, Roche/Genentech, Sanofi, Sutro, and Takeda; received honoraria from AbbVie, Janssen, Roche/Genentech, and Tecnopharma; and holds a membership on a board or advisory committee for Incyte and TG Therapeutics. BR received honoraria from Incyte, Bristol Myers Squibb, and PharmaEssentia. CR served as a consultant for Janssen, Bristol Myers Squibb, Takeda, AbbVie, Karyopharm, and Artiva; and served on a speakers bureau for Janssen, Bristol Myers Squibb, Takeda, AbbVie, Karyopharm, and Artiva. RS served as a consultant or in an advisory role for Sanofi-Aventis, Janssen Oncology, and Oncopeptides; and received research funding from Sanofi. LJC served as a consultant or in an advisory role for AbbVie, Amgen, Celgene, Karyopharm, and Sanofi; served on a speakers bureau for Amgen and Sanofi; received honoraria from Amgen, Celgene, Janssen, Karyopharm, and Sanofi; and received research funding from Amgen and Janssen. LDA holds a membership on an entity's board of directors or advisory committees for, served as a consultant for, and received honoraria from 10.1080/14796694.2024.2408909 Future Oncol. (Epub ahead of print) Final analysis of the GRIFFIN study of D-RVd for newly diagnosed multiple myeloma Plain Language Summary of Publication www.tandfonline.com GSK, Bristol Myers Squibb, Celgene, Janssen, Amgen, Oncopeptides, Karyopharm, AbbVie, and BeiGene. NS received research funding from Bristol Myers Squibb/Celgene, Janssen, bluebird bio, Sutro Biopharma, Teneobio, Poseida, Nektar, and Precision BioSciences; served as a consultant for GSK, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm, Oncopeptides, and CSL Behring; and is a current employee and equity holder of AstraZeneca. NB served on a speakers bureau for Amgen, Sanofi, and Genzyme; and served on an advisory board for Sanofi, Genzyme, and Janssen. YAE received research funding from, received honoraria from, and served on a speakers bureau for Janssen, Takeda, Oncopeptides, GSK, Pfizer, Sanofi, and Bristol Myers Squibb. SAH served as a consultant for Bristol Myers Squibb/Celgene, Janssen, Takeda, Pfizer, Oncopeptides, GSK, Secura Bio, and Sanofi; and received research funding from Oncopeptides. CC received honoraria from Regeneron, Takeda, Bristol Myers Squibb, Pfizer, and Janssen; and received research funding from Takeda, Bristol Myers Squibb, Pfizer, Janssen, Ionis, Harpoon, and Poseida. AJ served as a consultant or in an advisory role for and received honoraria from AbbVie, Amgen, Bristol Myers Squibb, Celgene, GSK, Gracell, Janssen, Karyopharm, and Sanofi. TMW served as a consultant for Carevive, Seattle Genetics, Janssen, and Sanofi. RZO received research funding from Asylia Therapeutics, Biotheryx, Heidelberg Pharma, CARsgen Therapeutics, Bristol Myers Squibb/Celgene, Exelixis, Janssen Biotech, Sanofi-Aventis, and Takeda Pharmaceuticals North America; received honoraria from and holds a membership on an entity's board of directors or advisory committees for AbbVie, Biotheryx, Bristol Myers Squibb, Janssen Biotech, Karyopharm, Meridian Therapeutics, Monte Rosa Therapeutics, Neoleukin Corporation, Oncopeptides, Regeneron Pharmaceuticals, Sanofi-Aventis, and Takeda Pharmaceuticals North America; and is a current stockholder of Asylia Therapeutics. KHS received honoraria from Bristol Myers Squibb, Janssen, GSK, Adaptive Biotechnologies, Sanofi, Takeda, and Amgen; served as an ad hoc member of advisory committees for GSK, Janssen, and Bristol Myers Squibb; served on a speakers bureau for GSK, Bristol Myers Squibb, Sanofi, Karyopharm, Takeda, Janssen, Adaptive Biotechnologies, and Amgen; and received research funding from AbbVie and Karyopharm. KHS is also the principal investigator of clinical trials sponsored by Janssen and Bristol Myers Squibb, with all research outside the scope of the submitted work. AJC served as a consultant for and received research funding from Janssen, Bristol Myers Squibb, and AbbVie; received research funding from Harpoon, Sanofi-Aventis, and Nektar; served as a consultant for Allogene, EUSA, GSK, and Secura Bio; and received research funding from and holds a membership on an entity's board of directors or advisory committees for Adaptive Biotechnologies. SD is the Executive Officer for Alliance Foundation Trials for Clinical Trials. KSG, HP, AC, SP, and TSL are current equity holders and employees of Janssen. SZU served as a consultant for Celgene, Amgen, Janssen Oncology, Seattle Genetics, Takeda, GSK, Karyopharm, AbbVie, SkylineDx, Merck, Oncopeptides, Genentech, Gilead Sciences, and Bristol Myers Squibb/Celgene; served on a speakers bureau for Takeda, Amgen, Janssen Oncology, Sanofi, and Bristol Myers Squibb/Celgene; and received research funding from Celgene and Array BioPharma. PGR received research funding from Oncopeptides, Bristol Myers Squibb/Celgene, Takeda, and Karyopharm; and served on advisory committees for Oncopeptides, Bristol Myers Squibb/Celgene, Takeda, Karyopharm, Janssen, Sanofi, Secura Bio, GSK, Regeneron, AstraZeneca, and Protocol Intelligence. NN declares no financial competing interests. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Competing interests disclosure
The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.
Writing disclosure
Editorial and medical writing support of this plain language summary were provided by Holly Clarke, PhD, and Charlotte Majerczyk, PhD, of Lumanity Communications Inc., and were funded by Janssen Global Services, LLC.